Skip to main content
. 2020 May 29;10:8753. doi: 10.1038/s41598-020-63033-4

Figure 1.

Figure 1

PFS (as determined by BICR) in the olaparib and chemotherapy TPC arms in the Asian subgroup and global OlympiAD study population. Data cut-off 9 December 2016; PFS data maturity, 77% (67/87 patients). BICR, blinded independent central review; bid, twice daily; CI, confidence interval; HR, hazard ratio; PFS, progression-free survival; TPC, treatment of physician’s choice.